Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07517042

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Led by Shanghai Zhongshan Hospital · Updated on 2026-04-08

420

Participants Needed

13

Research Sites

139 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.

CONDITIONS

Official Title

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult men or women aged 18 years or older
  • Simple obesity with a body mass index (BMI) of 28.0 to 45.0 kg/m²
  • Able and willing to provide written informed consent
Not Eligible

You will not qualify if you...

  • Active pulmonary tuberculosis, malignant tumors, HIV infection, or other serious infectious or systemic diseases
  • Severe liver impairment (AST or ALT more than 3 times upper limit of normal), severe kidney impairment, or end-stage kidney disease (eGFR less than 30 mL/min/1.73 m²)
  • Severe cardiovascular diseases, including angina, heart attack, or stroke within the past 6 months
  • Severe gastrointestinal diseases or history of gastrointestinal surgery within the past year
  • Acute or chronic pancreatitis, gallbladder disease, or pancreatic injury
  • Obesity caused by other conditions like Cushing's syndrome, hypothyroidism, hypothalamic obesity, acromegaly, or drug-related obesity
  • Current smoker or habitual smoking within the past 3 months
  • Current use of other weight-loss medications or history of weight-loss surgery
  • Diagnosed diabetes or current use of glucose-lowering medications
  • Pregnant, breastfeeding, or planning pregnancy during the study
  • Unable to complete a 2-year follow-up due to health, relocation, or other reasons
  • Any condition that the investigator judges makes participation unsuitable

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China, 400000

Actively Recruiting

2

Fujian Provincial Hospital, Affiliated to Fuzhou University

Fuzhou, Fujian, China, 350000

Actively Recruiting

3

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China, 361003

Actively Recruiting

4

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China, 430000

Actively Recruiting

5

Nanjing First Hospital, Nanjing Medical University

Nanjing, Jiangsu, China, 210000

Actively Recruiting

6

The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University

Suzhou, Jiangsu, China, 215000

Actively Recruiting

7

Huadong Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

8

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

9

Shanghai Tenth People's Hospital, School of Medicine, Tongji University

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

10

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200030

Actively Recruiting

11

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China, 646000

Actively Recruiting

12

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

13

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China, 325000

Actively Recruiting

Loading map...

Research Team

J

JINGJING JIANG, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management | DecenTrialz